The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
An autocrine signaling circuit in hepatic stellate cells underlies advanced fibrosis in nonalcoholic steatohepatitis
Open accessAbstract
Advanced hepatic fibrosis, driven by the activation of hepatic stellate cells (HSCs), affects millions worldwide and is the strongest predictor of mortality in nonalcoholic steatohepatitis (NASH); however, there are no approved antifibrotic therapies. To identify antifibrotic drug targets, we integrated progressive transcriptomic and morphological responses that accompany HSC activation in advanced disease using single-nucleus RNA sequencing and tissue clearing in a robust murine NASH model. In advanced fibrosis, we found that an autocrine HSC signaling circuit emerged that was composed of 68 receptor-ligand interactions conserved between murine and human NASH. These predicted interactions were supported by the parallel appearance of markedly increased direct stellate cell-cell contacts in murine NASH. As proof of principle, pharmacological inhibition of one such autocrine interaction, neurotrophic receptor tyrosine kinase 3–neurotrophin 3, inhibited human HSC activation in culture and reversed advanced murine NASH fibrosis. In summary, we uncovered a repertoire of antifibrotic drug targets underlying advanced fibrosis in vivo. The findings suggest a therapeutic paradigm in which stage-specific therapies could yield enhanced antifibrotic efficacy in patients with advanced hepatic fibrosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Recent single-cell human liver studies have largely focused on chronic liver disease rather than ALF, with emphasis on non-parenchymal cell populations7–9”
From Multimodal decoding of human liver regeneration (2024) · cites this paper as [9]
The cited source says what the claim attributes to it.
In the citing paper
“the FAT-MASH model was used, as this model reproducibly recapitulates the stages of progression of human MASH that include advanced fibrosis and tumors along with changes in the gut microbiome.14,33,34”
From EHBP1 suppresses liver fibrosis in metabolic dysfunction-associated steatohepatitis (2025) · cites this paper as [33]
In the citing paper
“We recently used single nuclear RNA-seq in murine MASH models and patients with MASH to demonstrate enrichment of pathways in myofibroblasts that regulate extracellular matrix production and cell migration, including matrix metalloproteinase (MMPs), tissue inhibitors of metalloproteinases (TIMPs), and lysyl oxidases (LOXLs) (47-49), similar to earlier studies of mouse fibrosis and human cirrhosis”
From Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH) (2023) · cites this paper as [48]
In the citing paper
“Our profiling of FAT-MASH macrophages using single nucleus RNA-seq showed no enrichment of ECM-related pathways, only induction of a few select matrix metalloproteinases (MMP2, matrix metalloproteinase 12 (MMP12), matrix metalloproteinase 14 (MMP14)) and decreased collagen type 18 alpha 1 (COL18A1) (48).”
From Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH) (2023) · cites this paper as [48]
In the citing paper
“The detection of both quiescent and activated HSCs in mouse liver injury models using single cell RNA-seq reinforces HSC activation as a driver of fibrosis common across etiologies that includes MASH (46-50).”
From Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH) (2023) · cites this paper as [48]
In the citing paper
“Although activated HSCs are the primary fibrogenic cells in MASH, these methods have identified an expanded list of fibrogenic drivers expressed by activated HSCs that could represent antifibrotic drug targets (42, 48, 49, 125).”
From Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH) (2023) · cites this paper as [48]
In the citing paper
“These different communication networks are reflected in the differential expression of ligand-receptor signaling pairs, suggesting that the repertoire of disease drivers – and therefore the underlying signaling events – may change as the disease advances, such that advanced fibrotic stages may respond to different pharmacotherapies than earlier stages (48, 49).”
From Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH) (2023) · cites this paper as [48]
In the citing paper
“Applying recent developments in informatic tools and databases (130, 131) has uncovered an altered cell-cell communication network in MASH based on the differential expression of ligands and receptors in different cell types (48, 49).”
From Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH) (2023) · cites this paper as [48]
In the citing paper
“It is worth noting that the FAT-MASH mice exhibit transcriptomic similarities to human MASH patients (48), and their microbiome changes also resemble human MASH pathology (197).”
From Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH) (2023) · cites this paper as [48]
In the citing paper
“To improve the quantitative measurement of fibrosis in liver biopsies, several robust platforms have been established that leverage machine or deep learning to precisely quantify not only the amount of scar, but also structural features of the extracellular matrix that may reflect progression or regression (48, 258, 290, 291).”
From Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH) (2023) · cites this paper as [48]
In the citing paper
“3) Identification of HSC subpopulations that are the main fibrosis drivers will lead to more targeted, safer therapies (42, 48).”
From Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH) (2023) · cites this paper as [48]
In the citing paper
“In advanced (human or rodent) hepatic fibrosis, HSC directly interacts with surrounding HSCs, driven by autocrine pathways that amplify fibrogenesis.112”
From An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH (2023) · cites this paper as [112]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mechanisms of NAFLD development and therapeutic strategies
Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M., & Sanyal, A. J. (2018) · Nature Medicine · doi:10.1038/s41591-018-0104-9 · Cited by 4,354
Self-citationEfremova, M., Vento-Tormo, M., Teichmann, S. A., & Vento-Tormo, R. (2020) · Nature Protocols · doi:10.1038/s41596-020-0292-x · Cited by 3,449
Angulo, P., Kleiner, D. E., Dam-Larsen, S., Adams, L. A., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Keach, J. C., Lafferty, H. D., Stahler, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.043 · Cited by 2,987
Mechanisms and disease consequences of nonalcoholic fatty liver disease
Loomba, R., Friedman, S. L., & Shulman, G. I. (2021) · Cell · doi:10.1016/j.cell.2021.04.015 · Cited by 2,002
Self-citationiDISCO: A Simple, Rapid Method to Immunolabel Large Tissue Samples for Volume Imaging
Renier, N., Wu, Z., Simon, D. J., Yang, J. H., Ariel, P., & Tessier‐Lavigne, M. (2014) · Cell · doi:10.1016/j.cell.2014.10.010 · Cited by 1,856
Cross-tissue organization of the fibroblast lineage
Buechler, M. B., Pradhan, R., Krishnamurty, A. T., Cox, C. B., Calviello, A. K., Wang, A. W., Yang, Y. A., Tam, L., Caothien, R. H., Roose‐Girma, M., et al. (2021) · Nature · doi:10.1038/s41586-021-03549-5 · Cited by 1,100
Human hepatic stellate cell lines, LX-1 and LX-2: new tools for analysis of hepatic fibrosis
Xu, L., Hui, A. Y., Albanis, E., Arthur, M. J., O’Byrne, S. M., Blaner, W. S., Mukherjee, P., Friedman, S. L., & Eng, F. J. (2004) · Gut · doi:10.1136/gut.2004.042127 · Cited by 1,020
Self-citationSpatial proteogenomics reveals distinct and evolutionarily conserved hepatic macrophage niches
Guilliams, M., Bonnardel, J., Haest, B., Vanderborght, B., Wagner, C., Remmerie, A., Bujko, A., Martens, L., Thoné, T., Browaeys, R., et al. (2022) · Cell · doi:10.1016/j.cell.2021.12.018 · Cited by 985
Vilar-Gomez, E., Calzadilla-Bertot, L., Wai-Sun Wong, V., Castellanos, M., Aller-de la Fuente, R., Metwally, M., Eslam, M., Gonzalez-Fabian, L., Alvarez-Quiñones Sanz, M., Conde-Martin, A. F., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.04.034 · Cited by 806
Xiong, X., Kuang, H., Ansari, S., Liu, T., Gong, J., Wang, S., Zhao, X.-Y., Ji, Y., Li, C., Guo, L., et al. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.07.028 · Cited by 784
Self-citation
Cited by
Sorted by citations
Hepatic inflammatory responses in liver fibrosis
Hammerich, L., & Tacke, F. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00807-x · Cited by 803
The NLRP3 inflammasome: contributions to inflammation-related diseases
Chen, Y., Ye, X., Escames, G., Lei, W., Zhang, X., Li, M., Jing, T., Yao, Y., Qiu, Z., Wang, Z., et al. (2023) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-023-00462-9 · Cited by 492
An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH
Tacke, F., Puengel, T., Loomba, R., & Friedman, S. L. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.03.038 · Cited by 321
Self-citationThe tumor microenvironment shows a hierarchy of cell-cell interactions dominated by fibroblasts
Mayer, S., Milo, T., Isaacson, A., Halperin, C., Miyara, S., Stein, Y., Lior, C., Pevsner‐Fischer, M., Tzahor, E., Mayo, A., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41518-w · Cited by 194
Self-citationMolecular mechanisms in MASLD/MASH-related HCC
Wang, X., Zhang, L., & Dong, B. (2024) · Hepatology · doi:10.1097/hep.0000000000000786 · Cited by 193
Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH)
Wang, S., & Friedman, S. L. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adi0759 · Cited by 158
Self-citationFriend or foe? The elusive role of hepatic stellate cells in liver cancer
Cogliati, B., Yashaswini, C. N., Wang, S., Sia, D., & Friedman, S. L. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00821-z · Cited by 159
Self-citationBhattacharya, M., & Ramachandran, P. (2023) · Nature Immunology · doi:10.1038/s41590-023-01551-9 · Cited by 148
Multimodal decoding of human liver regeneration
Matchett, K. P., Wilson-Kanamori, J. R., Portman, J. R., Kapourani, C. A., Fercoq, F., May, S., Zajdel, E., Beltran, M., Sutherland, E. F., Mackey, J. B. G., et al. (2024) · Nature · doi:10.1038/s41586-024-07376-2 · Cited by 140
“…the possible role of transdifferentiation (Reviewer #4) -Relate findings to clinical presentation (Reviewer #4) We thank the reviewers for their very helpful and thoughtful comments, and we feel that the new data we have generated in response to their comments has very much enhanced our manuscript.”
Self-citationSchwabe, R. F., & Brenner, D. A. (2025) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-025-01068-6 · Cited by 112
Ratziu, V., Hompesch, M., Petitjean, M., Serdjebi, C., Iyer, J. S., Parwani, A. V., Tai, D., Bugianesi, E., Cusi, K. J., Friedman, S. L., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.10.015 · Cited by 103
Self-citationmRNA nanodelivery systems: targeting strategies and administration routes
Yuan, M., Han, Z., Liang, Y., Sun, Y., He, B., Chen, W., & Fan, L. (2023) · Biomaterials Research · doi:10.1186/s40824-023-00425-3 · Cited by 98
Why Do So Many Nonalcoholic Steatohepatitis Trials Fail?
Ratziu, V., & Friedman, S. L. (2023) · Gastroenterology · doi:10.1053/j.gastro.2020.05.046 · Cited by 88
Self-citationYashaswini, C. N., Qin, T., Bhattacharya, D., Amor, C., Lowe, S. W., Lujambio, A., Wang, S., & Friedman, S. L. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.03.014 · Cited by 90
Self-citationKim, H. Y., Rosenthal, S. B., Liu, X., Miciano, C., Hou, X., Miller, M., Buchanan, J., Poirion, O., Chilin-Fuentes, D., Han, C., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.10.044 · Cited by 85
Self-citationAntifibrotic therapy in nonalcoholic steatohepatitis: time for a human-centric approach
Brennan, P. N., Elsharkawy, A. M., Kendall, T. J., Loomba, R., Mann, D. A., & Fallowfield, J. A. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00796-x · Cited by 68
Regulation of Hepatic Stellate Cell Phenotypes in Metabolic Dysfunction–Associated Steatohepatitis
Kisseleva, T., Ganguly, S., Murad, R., Wang, A., & Brenner, D. A. (2025) · Gastroenterology · doi:10.1053/j.gastro.2025.03.010 · Cited by 75
Self-citationThe Origin and Fate of Liver Myofibroblasts
Kim, H. Y., Sakane, S., Eguileor, A., Carvalho Gontijo Weber, R., Lee, W., Liu, X., Lam, K., Ishizuka, K., Rosenthal, S. B., Diggle, K., et al. (2024) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2023.09.008 · Cited by 63
Self-citationTsuchiya, Y., Seki, T., Kobayashi, K., Komazawa‐Sakon, S., Shichino, S., Nishina, T., Fukuhara, K., Ikejima, K., Nagai, H., Igarashi, Y., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42058-z · Cited by 57
Hess, A., Gentile, S. D., Saad, A. B., Rahman, R., Habboub, T., Pratt, D. S., & Mullen, A. C. (2023) · The EMBO Journal · doi:10.15252/embj.2023113898 · Cited by 56
Spatial genomics: mapping human steatotic liver disease
Matchett, K. P., Paris, J., Teichmann, S. A., & Henderson, N. C. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-024-00915-2 · Cited by 53
Self-citationSingle-cell and spatially resolved transcriptomics for liver biology
Lin, P., Yan, X., Jing, S., Wu, Y., Shan, Y., Guo, W., Gu, J., Li, Y., Zhang, H., & Li, H. (2023) · Hepatology · doi:10.1097/hep.0000000000000387 · Cited by 56
Mitochondrial DNA and the STING pathway are required for hepatic stellate cell activation
Arumugam, S., Li, B., Boodapati, S. L. T., Nathanson, M. H., Sun, B., Ouyang, X., & Mehal, W. Z. (2023) · Hepatology · doi:10.1097/hep.0000000000000388 · Cited by 51
Zhang, L., Deng, W., Huang, Q., Zhang, J., Wang, Y., Zhou, T., Xing, L., & Jiang, H. (2024) · Advanced Materials · doi:10.1002/adma.202311474 · Cited by 48
Antifibrotic therapies for metabolic dysfunction-associated steatotic liver disease
Schwabe, R. F., Tacke, F., Sugimoto, A., & Friedman, S. L. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101421 · Cited by 52
Self-citationTrinh, V. Q.-H., Lee, T.-F., Lemoinne, S., Ray, K. C., Ybanez, M. D., Tsuchida, T., Carter, J. K., Agudo, J., Brown, B. D., Akat, K. M., et al. (2023) · Science Signaling · doi:10.1126/scisignal.adf6696 · Cited by 45
Self-citationKhanal, S., Liu, Y., Bamidele, A. O., Wixom, A. Q., Washington, A. M., Jalan-Sakrikar, N., Cooper, S. A., Vuckovic, I., Zhang, S., Zhong, J., et al. (2024) · Science Advances · doi:10.1126/sciadv.adn5228 · Cited by 41
Liang, Y., Zhang, R., Biswas, S., Bu, Q., Xu, Z., Qiao, L., Zhou, Y., Tang, J., Zhou, J., Zhou, H., et al. (2023) · Cell Proliferation · doi:10.1111/cpr.13576 · Cited by 41
Tissue Biology: In Search of a New Paradigm
Adler, M., Chavan, A. R., & Medzhitov, R. (2023) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-120420-113830 · Cited by 40
Self-citationSingle cell-resolved study of advanced murine MASH reveals a homeostatic pericyte signaling module
Bendixen, S. M., Jakobsgaard, P. R., Hansen, D., Hejn, K. H., Terkelsen, M. K., Bjerre, F. A., Thulesen, A. P., Eriksen, N. G., Hallenborg, P., Geng, Y., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.11.001 · Cited by 40
Metabolic dysfunction and alcohol-associated liver disease (MetALD)
Gao, B., Arab, J. P., Liangpunsakul, S., Ding, W., Szabó, G., Mehal, W. Z., Wang, H., He, Y., Stärkel, P., Llorente, C., et al. (2025) · eGastroenterology · doi:10.1136/egastro-2025-100319 · Cited by 43
Sim, B. C., Kang, Y. E., You, S. K., Lee, S. E., Nga, H. T., Lee, H. Y., Nguyen, T. L., Moon, J. S., Tian, J., Jang, H. J., et al. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-06146-8 · Cited by 35
Hepatic Fibrosis and Cancer: The Silent Threats of Metabolic Syndrome
Friedman, S. L. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2023.0240 · Cited by 37
Self-citationDecoding organ fibrosis: mechanistic insights and emerging therapeutic strategies
Chen, X., Zhang, J., Guo, L., Wu, C., Zhou, J., Xu, M., Mo, L., Li, Y., & He, J. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02532-0 · Cited by 40
Therapeutic modulation of the liver immune microenvironment
Tilg, H., Adolph, T. E., & Tacke, F. (2023) · Hepatology · doi:10.1097/hep.0000000000000386 · Cited by 32
Recent insights into the pathogenesis and therapeutic targets of chronic liver diseases
Wen, Y., Ma, L., & Ju, C. (2023) · eGastroenterology · doi:10.1136/egastro-2023-100020 · Cited by 31
EHBP1 suppresses liver fibrosis in metabolic dysfunction-associated steatohepatitis
Ma, F., Longo, M., Meroni, M., Bhattacharya, D., Paolini, E., Mughal, S., Hussain, S., Anand, S. K., Gupta, N., Zhu, Y., et al. (2025) · Cell Metabolism · doi:10.1016/j.cmet.2025.01.020 · Cited by 29
Self-citationMechanisms of liver fibrosis in metabolic syndrome
Mehal, W. (2023) · eGastroenterology · doi:10.1136/egastro-2023-100015 · Cited by 28
Li, A., Wang, R., Zhao, Y. Q., Zhao, P., & Yang, J. (2024) · Metabolites · doi:10.3390/metabo14060325 · Cited by 29
Ratziu, V., Yilmaz, Y. N., Lazas, D. J., Friedman, S. L., Lackner, C., Behling, C. A., Cummings, O. W., Chen, L., Petitjean, M. M., Gilgun‐Sherki, Y., et al. (2024) · Hepatology · doi:10.1097/hep.0000000000000980 · Cited by 31
Self-citationAdvances in Extracellular Matrix-Associated Diagnostics and Therapeutics
Karsdal, M. A., Cox, T. R., Parker, A. L., Willumsen, N., Sand, J. M. B., Jenkins, G. R., Hansen, H. H., Oldenburger, A., Geillinger‐Kästle, K. E., Larsen, A. T., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14061856 · Cited by 29
Self-citationYashaswini, C. N., Cogliati, B., Qin, T., To, T., Williamson, T., Papp, T. E., Li, K., Rasul, R. B., Chen, L., Lightstone, A., et al. (2026) · Science Translational Medicine · doi:10.1126/scitranslmed.adx0368 · Cited by 47
Self-citationThe key players of inflammasomes and pyroptosis in sepsis-induced pathogenesis and organ dysfunction
Zhu, L., Hu, M., Xu, H., Xu, H., Ren, B., Xu, R., Guo, M., Chen, H., Zhang, D., & Fang, H. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1586364 · Cited by 31
Geng, Y., Wang, J., Salas, S. S., Villanueva, A. H., Buist‐Homan, M., Arrese, M. A., Olinga, P., Blokzijl, H., & Moshage, H. J. (2023) · Journal of Cellular Physiology · doi:10.1002/jcp.31086 · Cited by 26
Spatial single-cell omics: new insights into liver diseases
Suo, Y., Thimme, R., & Bengsch, B. (2025) · Gut · doi:10.1136/gutjnl-2024-332105 · Cited by 29
Hutchenreuther, J., Nguyen, J., Quesnel, K., Vincent, K. M., Petitjean, L., Bourgeois, S., Boyd, M., Bou–Gharios, G., Postovit, L.-M. M., & Leask, A. (2024) · Cancer Research Communications · doi:10.1158/2767-9764.crc-23-0571 · Cited by 26
Kostadinova, R. M., Ströbel, S., Chen, L., Fiaschetti‐Egli, K., Gadient, J., Pawlowska, A., Petitjean, L., Bieri, M., Thoma, E., & Petitjean, M. (2024) · Scientific Reports · doi:10.1038/s41598-024-55438-2 · Cited by 21
Self-citationPlasticity, heterogeneity, and multifunctionality of hepatic stellate cells in liver pathophysiology
Du, K., Jun, J. H., Dutta, R. K., & Diehl, A. M. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000411 · Cited by 28
A spatial atlas of the healthy human liver from live donors
Yakubovsky, O., Halpern, K. B., Shir, S., Novoselsky, R., Afriat, A., Egozi, A., Barkai, T., Harnik, Y., Hoefflin, R., Kohanim, Y. K., et al. (2026) · Nature · doi:10.1038/s41586-026-10377-y · Cited by 25
Cold and hot fibrosis define clinically distinct cardiac pathologies
Miyara, S., Adler, M., Umansky, K. B., Häußler, D., Bassat, E., Divinsky, Y., Elkahal, J., Kain, D., Lendengolts, D., Flores, R. O. R., et al. (2025) · Cell Systems · doi:10.1016/j.cels.2025.101198 · Cited by 28
Self-citationDissecting the mechanisms of MASLD fibrosis in the era of single-cell and spatial omics
Colella, F., Henderson, N. C., & Ramachandran, P. (2025) · Journal of Clinical Investigation · doi:10.1172/jci186421 · Cited by 25
Self-citationSingle-cell multiomics guided mechanistic understanding of Fontan-associated liver disease
Hu, P., Rychik, J. R., Zhao, J., Bai, H., Bauer, A., Yu, W., Rand, E. B., Dodds, K. M., Goldberg, D., Tan, K., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adk6213 · Cited by 26
AI‐Assisted Drug Re‐Purposing for Human Liver Fibrosis
Guan, Y., Cui, L., Inchai, J., Fang, Z., Law, J., Brito, A. A. G., Pawlosky, A., Gottweis, J., Daryin, A., Myaskovsky, A., et al. (2025) · Advanced Science · doi:10.1002/advs.202508751 · Cited by 25
Lhx2 specifically expressed in HSCs promotes liver regeneration and inhibits liver fibrosis
Tao, J., Wu, Z., Liang, Y., Wang, J., Tang, M., Huang, S., Jiang, F., Zhou, G., Guo, L., Yuan, S., et al. (2025) · Hepatology · doi:10.1097/hep.0000000000001201 · Cited by 19
Xiong, H., & Guo, J. (2025) · Pharmaceuticals · doi:10.3390/ph18040507 · Cited by 22
“The Good, the Bad, and the Ugly” – About Diverse Phenotypes of Hepatic Stellate Cells in the Liver
Bogomolova, A., Balakrishnan, A., Ott, M., & Sharma, A. D. (2024) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2024.01.002 · Cited by 18
Ahamed, F., Eppler, N., Jones, E., & Zhang, Y. (2024) · Livers · doi:10.3390/livers4030033 · Cited by 17
Fujiwara, N., & Nakagawa, H. (2023) · Cancer Science · doi:10.1111/cas.15925 · Cited by 14
The pivotal role of dysregulated autophagy in the progression of non-alcoholic fatty liver disease
Shen, Q., Yang, M., Wang, S., Chen, X., Chen, S., Zhang, R., Xiong, Z., & Leng, Y. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1374644 · Cited by 15
Self-citationWerge, M. P., Grandt, J., Thing, M., Hetland, L. E., Rashu, E. B., Jensen, A. H., Junker, A. E., Richter, M. M., Møller, S., Bendtsen, F., et al. (2024) · Hepatology Research · doi:10.1111/hepr.14148 · Cited by 16
Temporal tissue dynamics from a spatial snapshot
Somer, J., Mannor, S., & Alon, U. (2026) · Nature · doi:10.1038/s41586-025-09876-1 · Cited by 20
Self-citationMeng, Z., Zhou, L., Hong, S., Qiu, X., Chen, Z., Liu, T., Inoki, K., & Lin, J. D. (2023) · Hepatology · doi:10.1097/hep.0000000000000537 · Cited by 16
Zhang, L., Deng, W., Wang, X., Huang, Q., Liang, S., Ding, Z., Qi, L., Wang, Y., Zhou, T., Xing, L., et al. (2024) · Advanced Science · doi:10.1002/advs.202408898 · Cited by 15
Liu, J., Hu, S., Chen, L., Daly, C., Prada‐Medina, C. A., Richardson, T. G., Traylor, M., Dempster, N. J., Mbasu, R. J., Monfeuga, T., et al. (2023) · medRxiv · doi:10.1101/2023.11.30.23299247 · Cited by 22
Self-citationYashaswini, C. N., Cogliati, B., Qin, T., To, T., Williamson, T., Papp, T. E., Li, K., Rasul, R., Chen, L., Lightstone, A., et al. (2025) · doi:10.1101/2025.02.25.640143 · Cited by 13
Self-citationEmerging mechanisms of non-alcoholic steatohepatitis and novel drug therapies
Hao, C. H. E. N., Zhou, Y., Hao, H., & XIONG, J. (2024) · Chinese Journal of Natural Medicines · doi:10.1016/s1875-5364(24)60690-4 · Cited by 15
Wang, L., Huang, Y., Chen, J., Gao, J., Chen, S., Zhao, M., Lin, J., Zhou, S., Shen, Y., & Cheng, Y. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1635763 · Cited by 15
Friedman, S. L., & Sanyal, A. J. (2023) · Hepatology · doi:10.1097/hep.0000000000000389 · Cited by 12
Self-citationTan, P. K., Ostertag, T. M., Rosenthal, S. B., Chilin-Fuentes, D., Aidnik, H., Linker, S. B., Murphy, K., Miner, J. N., & Brenner, D. A. (2023) · American Journal Of Pathology · doi:10.1016/j.ajpath.2023.12.005 · Cited by 12
Sex differences in murine MASH induced by a fructose-palmitate-cholesterol-enriched diet
Arivazhagan, L., Delbare, S., Wilson, R. A., Manigrasso, M. B., Zhou, B., Ruiz, H. H., Mangar, K., Higa, R., Brown, E., Li, H., et al. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101222 · Cited by 14
Smart Microneedle Arrays Integrating Cell‐Free Therapy and Nanocatalysis to Treat Liver Fibrosis
Xu, Y., Zhang, Y., Tian, H., Zhong, Q., Yi, K., Li, F., Xue, T., Wang, H., Lao, Y., Xu, Y., et al. (2024) · Advanced Science · doi:10.1002/advs.202309940 · Cited by 19
Self-citationHepatic Stellate Cells Functional Heterogeneity in Liver Cancer
Sererols-Viñas, L., Garcia‐Vicién, G., Ruiz-Blázquez, P., Lee, T., Lee, Y. A., Gonzalez‐Sanchez, E., Vaquero, J., Moles, A., Filliol, A. A., & Affò, S. (2025) · Seminars in Liver Disease · doi:10.1055/a-2551-0724 · Cited by 16
Ye, M., He, Y., Xia, Y. Y., Zhong, Z., Kong, X., Zhou, Y., Xia, W., Wang, W., Fan, H., Chen, L., et al. (2024) · Biological Trace Element Research · doi:10.1007/s12011-024-04261-x · Cited by 10
Self-citationHuang, P., Wei, G., Kirkpatrick, J. D., Lin, Y., Tan, L., Matta, H., Nasser, I. A., Huang, M., Chen, L., Petitjean, M. M., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.07.016 · Cited by 10
Self-citationSun, L., Shao, Y., Zhuang, Z.-H., Liu, Z., Liu, M., Qu, C., & Haojun, Y. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112831 · Cited by 10
Naoumov, N. V., Kleiner, D. E., Chng, E., Brees, D., Saravanan, C., Ren, Y., Tai, D., & Sanyal, A. J. (2024) · Liver International · doi:10.1111/liv.16092 · Cited by 11
GPNMB regulates the differentiation and transformation of monocyte-derived macrophages during MASLD
Wang, J., Wang, H., Yang, W., Zhao, D., Liu, D., Tang, L., & Chen, X. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114554 · Cited by 12
Natural killer cell therapy in hepatocellular carcinoma: a comprehensive review
Tavakoli, S., Salavatipour, M. S., Rahnama, M. A., Abdolahi, S., Hassanzadeh, A., Ghazvinian, Z., Verdi, J., Vousooghi, N., Manoochehrabadi, S., Chahardouli, B., et al. (2025) · Discover Oncology · doi:10.1007/s12672-025-03138-2 · Cited by 14
Vu, H., Sun, Y., Xiong, Z., Tan, X., Radford‐Smith, D. E., Causer, A., Dickens, A. M., Hyötyläinen, T., Evstafev, I., Orešič, M., et al. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101657 · Cited by 13
Ning, M., Lu, D., Liang, D., & Ren, P. (2025) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2025.1513993 · Cited by 10
He, Q., Yin, Y., Xu, Y., Tan, X., Wang, Y.-C., & Zhang, W. (2025) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2025.119068 · Cited by 9
Sodium nitrate protects against metabolic syndrome by sialin-mediated macrophage rebalance
Li, S., Wang, Y., Zhang, Z., Xu, H., Wu, S., Jin, H., Han, X., Liu, Y., Wen, X., Wu, Y., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02418-1 · Cited by 12
Self-citationYashaswini, C. N., Mitran, B., Papadopoulos, N., Wegrzyniak, O., Löfblom, J., Nordström, H., Velikyan, I., Abouzayed, A., Johansson, L., Hagmar, P., et al. (2025) · EJNMMI Radiopharmacy and Chemistry · doi:10.1186/s41181-025-00410-2 · Cited by 9
Self-citationEmerging Roles of Spatial Transcriptomics in Liver Research
Fujiwara, N., Kimura, G., & Nakagawa, H. (2024) · Seminars in Liver Disease · doi:10.1055/a-2299-7880 · Cited by 12
M. S. Barron, A., Fabre, T., & De, S. (2024) · F1000Research · doi:10.12688/f1000research.143472.1 · Cited by 8
Ganguin, A. A., Skorup, I., Streb, S., Othman, A., & Luciani, P. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202300811 · Cited by 8
Rosenstein, R. K., Rose, J. J., Brooks, S. R., Tsai, W. L., Gadina, M., Pavletic, S. Z., Nagao, K., & Cowen, E. W. (2023) · JID Innovations · doi:10.1016/j.xjidi.2023.100246 · Cited by 8
EphB2 Receptor Promotes Dermal Fibrosis in Systemic Sclerosis
Egal, É. S. A., Kamdem, S. D., Yoshigi, M., Yang, C., Pellizzari, S., Kameni, E. M., Helms, M. N., Assassi, S., Henkemeyer, M. J., Frech, T., et al. (2024) · Arthritis & Rheumatology · doi:10.1002/art.42858 · Cited by 7
ZBED3 exacerbates hyperglycemia by promoting hepatic gluconeogenesis through CREB signaling
Luo, Y., Ruan, C.-S., Zhao, F.-Z., Yang, M., Cui, W., Cheng, X., Luo, X.-H., Zhang, X.-X., & Zhang, C. (2024) · Metabolism · doi:10.1016/j.metabol.2024.156049 · Cited by 8
Seki, T., Komazawa-Sakon, S., Nishina, T., Mikami, T., Yagita, H., Okunishi, K., Tanaka, M., Tsuchiya, Y., & Nakano, H. (2025) · iScience · doi:10.1016/j.isci.2025.112932 · Cited by 6
Moreno, J., Gluud, L. L., Galsgaard, E. D., Hvid, H., Mazzoni, G., & Das, V. (2024) · PLoS ONE · doi:10.1371/journal.pone.0302853 · Cited by 8
Papachristoforou, E., Kong, K., Colella, F., Tam, J., Luft, J., Sutherland, E. F., Veizades, S. A., Grzelka, M., Qui, P. K., Asif, A., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.08.27.671899 · Cited by 7
Self-citationScar-associated endothelial-stellate cellular crosstalk drives fibrosis resolution in MASH
Li, K., Kumar, V., To, T., González‐Domínguez, Á., Huria, J., Yu, M., Cogliati, B., Yashaswini, C. N., Miller, C. M., Branch, A. D., et al. (2026) · Cell Reports · doi:10.1016/j.celrep.2025.116915 · Cited by 7
Self-citationA Critical Role for the Mitochondrial Pyruvate Carrier in Hepatic Stellate Cell Activation
Habibi, M., Ferguson, D., Eichler, S. J., Chan, M. M., Fu, C. F., Pietka, T., Bredemeyer, A. L., LaPoint, A., Shew, T. M., He, M., et al. (2025) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2025.101517 · Cited by 6
Hepatic stellate cells: From bad reputation to mediators of liver homeostasis
Schönberger, K., & Tchorz, J. S. (2023) · Science Signaling · doi:10.1126/scisignal.adh5460 · Cited by 6
Jerala, M., Remic, T., Hauptman, N., Homan, P., Zajšek, N., Petitjean, M., Chen, L., & Zidar, N. (2024) · Scientific Reports · doi:10.1038/s41598-024-64672-7 · Cited by 5
Self-citationHabibi, M., Ferguson, D., Eichler, S. J., Chan, M. M., LaPoint, A., Shew, T. M., He, M., Lutkewitte, A. J., Schilling, J. D., Cho, K., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.02.13.528384 · Cited by 5
Towards a reference cell atlas of liver diversity over the human lifespan
Taylor, S. A., Bader, G. D., MacParland, S. A., Mullen, A. C., Andrews, T. S., Cuenca, A. G., DasGupta, R., Gehring, A. J., Grün, D., Guilliams, M., et al. (2025) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-025-01114-3 · Cited by 5
Self-citationFu, R., Zhang, F., Fu, J., Li, Y., Zhu, X., Ding, Q., & Zhu, Y. Z. (2025) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2025.163 · Cited by 6
Effect of free fatty acids on TGF-β1 mediated fibrogenesis in hepatic stellate cells
Nardo, W. D., Bayliss, J., Doomun, S. N. E., Lee, O., Miotto, P. M., Suriani, N. D., Nie, S., Leeming, M., Miranda, D. A., Souza, D. P. D., et al. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102309 · Cited by 6
Metadata
- Authors
- Wang, S., Li, K., Pickholz, E., Dobie, R., Matchett, K. P., Henderson, N. C., Carrico, C., Driver, I., Borch Jensen, M., Chen, L., Petitjean, M., Bhattacharya, D., Fiel, M. I., Liu, X., Kisseleva, T., Alon, U., Adler, M., Medzhitov, R., & Friedman, S. L.
- Affiliations
- Icahn School of Medicine at Mount Sinai (US)
- Centre for Inflammation Research (GB)
- Gordian Biotechnology, San Francisco, CA 94107, USA.
- PharmaNest Inc., Princeton, NJ 08540, USA.
- University of California San Diego (US)
- Weizmann Institute of Science (IL)
- Yale University (US)
- Howard Hughes Medical Institute (US)
- Corresponding author
- Friedman, Scott L.
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2023-01-04
- Volume
- 15
- Issue
- 677
- Pages
- eadd3949-eadd3949
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- PMC
- PMC10686705
- OpenAlex
- W4313544888
- Cited by
- 176
- References
- 31
- Citations by year
- 2026: 43 · 2025: 51 · 2024: 40 · 2023: 41
- FWCI
- 29.29
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- American Gastroenterological Association
- Wellcome Trust (219542/Z/19/Z)
- Cancer Research UK (A27145, 27145, C19767/A27145)
- National Institutes of Health (DK120515, UL1TR004419)
- National Institute on Alcohol Abuse and Alcoholism (U01AA029019, R01AA028550, P50AA011999)
- National Cancer Institute (P30CA196521)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK111866, R01DK056621, R01DK128289, R01DK136016, P30DK120515, R01DK101737, R01DK099205)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Keywords
- hepatic stellate cells, nonalcoholic steatohepatitis, liver fibrosis, autocrine signaling, ligand-receptor interactions, NTRK3, neurotrophin-3, stellate cell activation, single-nucleus RNA sequencing, tissue clearing
- MeSH terms
- Animals, Fibrosis, Humans, Liver, Liver Cirrhosis, Autocrine Communication, Mice, Hepatic Stellate Cells, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
